ScreenerHero

OBX Obsidian Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · obsidiantx.com
13.20USD-0.15%Mkt Cap: 815.40M $P/E: —

Obsidian Therapeutics, Inc. operates as a clinical-stage biotechnology company developing engineered cell and gene therapies. The company is developing investigational therapies, including OBX-115, which is being evaluat…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap815.40M USD
Enterprise Value1.12B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-100.61M USD
Revenue/Share—
Last Price13.20 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees87
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-6.21
PEG—
EV/EBITDA-11.63
EV/Revenue—
P/S—
P/B-0.98
EPS (TTM)-1.55
EPS (Forward)-2.13
52W Range
12.163% of range49.97
52W High49.97 USD
52W Low12.16 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE37.82%
ROA-113.58%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-90.39M USD
CapEx (TTM)73.00K USD
FCF Margin—
FCF Yield—
Net Debt-31.54M USD
Net Debt/EBITDA0.33
Balance Sheet
Debt/Equity-0.02
Current Ratio2.29
Quick Ratio1.71
Book Value/Sh-13.51 USD
Cash/Share0.56 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)39.00 USD
Upside (mean)+195.5%
Target Range32.00 USD – 43.00 USD
32.00+195.5% to mean43.00
# Analysts3
Ownership
Shares Out.61.77M
Float52.95M
Insiders0.81%
Institutions28.29%
Short Interest
Short Ratio0.9d
Short % Out.0.41%
Shares Short253.08K
Short (prev mo.)36.10K
Technical
SMA 5018.81 (-29.8%)
SMA 20018.81 (-29.8%)
Beta2.64
S&P 52W Chg16.45%
Avg Vol (30d)571.66K
Avg Vol (10d)498.65K
Technical Indicators
RSI (14)39.7
MACD-1.4166
MACD Signal-1.3447
MACD Hist.-0.0719
BB Upper19.35 USD
BB Middle15.36 USD
BB Lower11.37 USD
BB Width51.95%
ATR (14)1.904 USD
Vol Ratio (20d)0.47x